David DeSalvo serves as Vice President of Combination Product Development at Kindeva Drug Delivery, where he leads the development of drug-device combination products that connect life-changing therapies with patients around the world. With over 25 years of experience in drug delivery innovation and commercial leadership, David plays a central role in driving Kindeva’s mission of Manufacturing More Tomorrows™ by advancing combination product solutions from concept to launch.

A purpose-driven leader and award-winning innovator, David has led the creation, development, and successful market introduction of dozens of combination products collaboration with the world’s leading pharmaceutical and biotech companies. His work has contributed to several of the most commercially successful and clinically impactful drug delivery devices in the industry. In addition to his technical leadership, David has negotiated and secured numerous licensing, development, and manufacturing agreements that have delivered measurable enterprise growth and value to partners and patients.

Before joining Kindeva, David held senior roles at global life science and medical device organizations, including Emergent BioSolutions, Nuance Designs, SHL Medical, and Becton Dickinson (BD). Throughout his career, he has combined deep technical expertise with business acumen to guide cross-functional teams and advance pioneering combination products.

David holds a Bachelor’s and Master’s degree in Mechanical Engineering from Rensselaer Polytechnic Institute and an MBA from Marist College. His broad technical background, strategic mindset, and commitment to collaboration reflect Kindeva’s identity as a purpose-fueled, people-centric CDMO dedicated to advancing client projects, partner ambitions, and the future of drug delivery.

Chun Wang is a co-founder and Chief Scientific Officer of Trekka Therapeutics, LLC (http://trekkatherapeutics.com), a startup company developing next-generation healthcare products based on the proprietary CAPRO TM polymers, a novel class of excipients. He is also on the faculty of the Department of Biomedical Engineering, University of Minnesota, and directs the Polymeric Biomaterials Lab at Minnesota (http://biomaterials.umn.edu). His past and current research covers a broad range of topics, including polymeric hydrogels, micelles, nanoparticles, biointerfaces, stimuli-responsive and biodegradable polymers for controlled release and drug delivery. He has published over 100 research articles and reviews and given over 130 invited talks. He holds numerous patents (5 issued, 2 pending). He served on the editorial board of the Journal of Controlled Release (2006-2016) and is currently on the boards of Advanced Drug Delivery Reviews, Pharmaceutics, and Frontiers in Biomaterials Science as the Specialty Chief Editor for Delivery Systems and Controlled Release. He was a recipient of the NSF CAREER Award, a Wallace H. Coulter Foundation Early Career Translational Research Award, and the UMN McKnight Land-Grant Professorship. He received his Ph.D. in Bioengineering from the University of Utah and was an NIH NRSA Postdoctoral Fellow at the Massachusetts Institute of Technology.